Bonafton^® (Ointment) Instructions for Use

Instructions
Dosage forms

ATC Code

D06BB (Antiviral drugs)

Clinical-Pharmacological Group

Antiviral drug for external and topical use

Pharmacotherapeutic Group

Antiviral agent for topical application

Pharmacological Action

Antiviral drug, active against Herpes simplex virus and some adenoviruses.

It suppresses the synthesis of cytoplasmic proteins that are incorporated into the capsids and disrupts the transport of viral capsid components into the cell nucleus where their assembly takes place.

Pharmacokinetics

Pharmacokinetic data for the drug are not available.

Indications

Viral diseases

Of the skin;
Of the mucous membranes of the oral cavity and genitals (herpes simplex, herpes zoster; condyloma acuminatum);
Herpetic stomatitis and gingivitis.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
A60	Anogenital herpesviral infection [herpes simplex]
A63.0	Anogenital [venereal] warts (condyloma acuminatum)
B00	Herpesviral [herpes simplex] infections
B00.2	Herpetic gingivostomatitis and pharyngotonsillitis
B02	Zoster [herpes zoster]

ICD-11 code	Indication
1A94.Z	Anogenital herpes simplex virus infection without further specification
1A95.Z	Anogenital warts, unspecified
1E91.Z	Herpes zoster, unspecified
1F00.0	Infection of skin or mucous membranes caused by herpes simplex virus
1F00.02	Gingivostomatitis caused by herpes simplex virus
1F00.Z	Infections due to herpes simplex virus, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Ointment

Topically, externally.

For herpes simplex and herpes zoster, the drug is applied in a thin layer to the affected areas of the skin 3-4 times a day (in the genital area – 4-6 applications per day).

Treatment is carried out in 3 cycles of 5 days each with 1-2-day breaks or 2 cycles of 10 days each with a 3-5-day break.

For diseases of the oral mucosa, the drug is applied in a thin layer to the affected areas 4-6 times a day (the course of treatment is 3-20 days depending on the severity of the disease).

For the treatment of condyloma acuminatum, the drug is used 2 times a day for 2 weeks.

Treatment with the ointment is combined with oral administration of Bonafton^® tablets, soluble in the intestine.

Adverse Reactions

Allergic reactions. Dermatitis.

Contraindications

Hypersensitivity to the drug components;
Pregnancy and lactation;
Children under 18 years of age.

Use in Pregnancy and Lactation

Contraindicated during pregnancy and lactation.

Pediatric Use

Contraindicated in children under 18 years of age.

Special Precautions

Effect on the ability to drive vehicles and mechanisms

The drug does not have a negative effect on the performance of potentially hazardous activities requiring special attention and quick reactions (driving a car, etc.).

Overdose

To date, no cases of drug overdose have been reported.

Drug Interactions

No pharmacological interaction with other drugs has been identified.

Storage Conditions

At a temperature not exceeding 25°C (77°F). Keep out of reach of children.

Shelf Life

Shelf life – 2 years.

Dispensing Status

By prescription.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer